Want to see NXTC full AI Analyst Report?
NextCure (NXTC) Stock Statistics & Valuation Metrics
Total Valuation
NextCure has a market cap or net worth of $28.88M. The enterprise value is -$7.31M.
- Market Cap
- $28.88M
- Enterprise Value
- -$7.31M
Share Statistics
NextCure has 4,577,359 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 4,577,359
- Owned by Insiders
- 22.76%
- Owned by Institutions
- 35.52%
Financial Efficiency
NextCure’s return on equity (ROE) is -1.60 and return on invested capital (ROIC) is -141.83%.
- Return on Equity (ROE)
- -1.60
- Return on Assets (ROA)
- -1.11
- Return on Invested Capital (ROIC)
- -141.83%
- Return on Capital Employed (ROCE)
- -1.45
- Revenue Per Employee
- 0
- Profits Per Employee
- -1.40M
- Employee Count
- 40
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of NextCure is -0.60. NextCure’s PEG ratio is -0.01.
- PE Ratio
- -0.60
- PS Ratio
- 0.00
- PB Ratio
- 2.76
- Price to FCF
- -0.78
- Price to Operating Cash Flow
- -0.91
- PEG Ratio
- -0.01
Income Statement
In the last 12 months, NextCure had revenue of 0 and earned -55.84M in profits. Earnings per share was -19.65.
- Revenue
- 0
- Gross Profit
- -2.19M
- Operating Income
- -57.62M
- Pretax Income
- -55.84M
- Net Income
- -55.84M
- EBITDA
- -53.66M
- Earnings Per Share (EPS)
- -19.65
Cash Flow
In the last 12 months, operating cash flow was -36.98M and capital expenditures 0, giving a free cash flow of -36.98M billion.
- Operating Cash Flow
- -36.98M
- Free Cash Flow
- -36.98M
- Free Cash Flow per Share
- -6.97
Dividends & Yields
NextCure pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -128.05%
- Earnings Yield
- -127.59%
Stock Price Statistics
- Beta
- 1.19
- 52-Week Price Change
- -48.49%
- 50-Day Moving Average
- 6.13
- 200-Day Moving Average
- 7.75
- Relative Strength Index (RSI)
- 54.31
- Average Volume (3m)
- 146.54K
Important Dates
NextCure upcoming earnings date is Mar 04, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Oct 29, 2026
- Next Earnings Date
- Mar 04, 2027
- Ex-Dividend Date
- ―
Financial Position
NextCure as a current ratio of 4.14, with Debt / Equity ratio of 14.75%
- Current Ratio
- 4.14
- Quick Ratio
- 4.14
- Debt to Market Cap
- 0.10
- Net Debt to EBITDA
- 0.39
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, NextCure has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
NextCure EV to EBITDA ratio is -0.43, with an EV/FCF ratio of -0.48.
- EV to Sales
- 0.00
- EV to EBITDA
- -0.43
- EV to Free Cash Flow
- -0.48
- EV to Operating Cash Flow
- -0.48
Balance Sheet
NextCure has $20.09M in cash and marketable securities with $4.29M in debt, giving a net cash position of $15.80M billion.
- Cash & Marketable Securities
- $20.09M
- Total Debt
- $4.29M
- Net Cash
- $15.80M
- Net Cash Per Share
- $3.45
- Tangible Book Value Per Share
- $2.29
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for NextCure is $20.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
- Price Target
- $20.00
- Price Target Upside
- 216.96% Upside
- Analyst Consensus
- Moderate Buy
- Analyst Count
- 1
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- 59.14%
Scores
- Smart Score
- ―
- AI Score
- 45